These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 17479959)

  • 41. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
    Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification and Functional Validation of a Biomarker for the Diagnosis of Miltefosine Relapse during Visceral Leishmaniasis.
    Tiwary P; Kumar D; Sundar S
    Am J Trop Med Hyg; 2018 Feb; 98(2):492-496. PubMed ID: 29280431
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.
    Pérez-Victoria FJ; Sánchez-Cañete MP; Seifert K; Croft SL; Sundar S; Castanys S; Gamarro F
    Drug Resist Updat; 2006; 9(1-2):26-39. PubMed ID: 16814199
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India.
    Bhattacharya SK; Jha TK; Sundar S; Thakur CP; Engel J; Sindermann H; Junge K; Karbwang J; Bryceson AD; Berman JD
    Clin Infect Dis; 2004 Jan; 38(2):217-21. PubMed ID: 14699453
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Miltefosine for Indian visceral leishmaniasis.
    Roca B
    N Engl J Med; 2003 Feb; 348(9):857-8; author reply 857-8. PubMed ID: 12608397
    [No Abstract]   [Full Text] [Related]  

  • 46. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Mucocutaneous leishmaniasis in Morocco, evidence of the parasite's ecological evolution?].
    Iguermia S; Harmouche T; Mikou O; Amarti A; Mernissi FZ
    Med Mal Infect; 2011 Jan; 41(1):47-8. PubMed ID: 20947275
    [No Abstract]   [Full Text] [Related]  

  • 48. Miltefosine for visceral leishmaniasis.
    Eibl H
    N Engl J Med; 2000 Mar; 342(12):894-5. PubMed ID: 10733376
    [No Abstract]   [Full Text] [Related]  

  • 49. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
    Ramesh V; Ansari NA; Jain RK; Salotra P
    Clin Exp Dermatol; 2008 Jan; 33(1):103-5. PubMed ID: 17979988
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
    Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
    Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis.
    Sampaio RNR; Silva JSFE; Paula CDR; Porto C; Motta JOCD; Pereira LIA; Martins SS; Barroso DH; Freire GSM; Gomes CM
    Rev Soc Bras Med Trop; 2019 Mar; 52():e20180292. PubMed ID: 30942258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Miltefosine for Indian visceral leishmaniasis.
    Agarwal PK
    N Engl J Med; 2003 Feb; 348(9):857-8; author reply 857-8. PubMed ID: 12606744
    [No Abstract]   [Full Text] [Related]  

  • 54. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1.
    Schraner C; Hasse B; Hasse U; Baumann D; Faeh A; Burg G; Grimm F; Mathis A; Weber R; Günthard HF
    Clin Infect Dis; 2005 Jun; 40(12):e120-4. PubMed ID: 15909255
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Miltefosine for visceral leishmaniasis.
    Sherwood JA
    N Engl J Med; 2000 Mar; 342(12):895. PubMed ID: 10733377
    [No Abstract]   [Full Text] [Related]  

  • 56. Cutaneous leishmaniasis with lymphadenopathy due to Leishmania donovani.
    Faber WR; Wonders J; Jensema AJ; Chocholova E; Kager PA
    Clin Exp Dermatol; 2009 Jul; 34(5):e196-8. PubMed ID: 19077092
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Miltefosine and cutaneous leishmaniasis.
    Machado PR; Penna G
    Curr Opin Infect Dis; 2012 Apr; 25(2):141-4. PubMed ID: 22248979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. First case of typical Old World cutaneous leishmaniasis treated with miltefosine.
    Stojkovic M; Junghanss T; Krause E; Davidson RN
    Int J Dermatol; 2007 Apr; 46(4):385-7. PubMed ID: 17442078
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Breakthrough in the management of visceral leishmaniasis.
    Thakur BB
    J Assoc Physicians India; 2003 Jul; 51():649-51. PubMed ID: 14621030
    [No Abstract]   [Full Text] [Related]  

  • 60. Miltefosine: issues to be addressed in the future.
    Berman J; Bryceson AD; Croft S; Engel J; Gutteridge W; Karbwang J; Sindermann H; Soto J; Sundar S; Urbina JA
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S41-4. PubMed ID: 16750231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.